Ultragenyx Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on August 22, 2018. The filing addresses a temporary suspension of trading under the Company's employee benefit plans, specifically the Ultragenyx Pharmaceutical Inc. 401(k) Plan and Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is administrative in nature and does not contain financial performance data.
Material Changes
The material event reported is the implementation of a trading blackout period for directors and executive officers. This restriction is due to the transition of the 401(k) Plan to a new record keeper, custodian, and trustee.
Outlook, Risks, and Unusual Items
- Blackout Period Dates: The period began on August 24, 2018, at 4:00 PM ET/1:00 PM PT and is expected to end during the week of September 30, 2018. The exact end date depends on the finalization of the transition.
- Restrictions: During this period, participants cannot change deferral elections, investment options, or request loans/distributions. Directors and executive officers are prohibited from purchasing, selling, or transferring Company equity securities, with limited exceptions.
- Contact Information: Interested parties may obtain information regarding the blackout period by contacting Karah Parschauer, Executive Vice President and General Counsel.
Investor Verification Checklist
- Confirm the actual end date of the blackout period once the transition to the new record keeper is finalized.
- Verify that no other material events were disclosed in concurrent filings.
- Note that this filing does not impact the Company's financial statements or operational guidance.